Bristol-Myers Squibb (BMY) Given Media Impact Rating of 0.36

Media headlines about Bristol-Myers Squibb (NYSE:BMY) have trended positive on Wednesday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a news impact score of 0.36 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.6170259071052 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Bristol-Myers Squibb (BMY) traded down $0.45 during trading hours on Wednesday, hitting $62.02. The stock had a trading volume of 4,828,800 shares, compared to its average volume of 8,452,800. The stock has a market capitalization of $99,860.00, a price-to-earnings ratio of 21.10, a PEG ratio of 2.37 and a beta of 1.17. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the company posted $0.77 EPS. equities research analysts forecast that Bristol-Myers Squibb will post 2.99 EPS for the current fiscal year.

Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday. Goldman Sachs Group restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group restated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Finally, Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $64.93.

In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply